Health officials have given a life-extending drug the green light for widespread NHS, giving hope to thousands of men facing a "death sentence" from prostate cancer.
The National Institute for Health and Care Excellence (Nice) said the drug enzalutamide, also known as xtandi, should be considered for use in the treatment of men with hormone relapsed prostate cancer that has spread to other parts of the body.
Nice said in its draft guidance that it was pleased to recommend the drug, which is manufactured by Astellas Pharma, for patients who have few other treatment options left.
More top news
Burnley have apologised to Bradford after one of their supporters was ejected from Saturday's pre-season friendly at Valley Parad
Two British schoolchildren seriously injured in a coach crash on the Swiss border remain in hospital in France.
Mixed set up this Sunday